Format

Send to

Choose Destination
Curr Opin Pharmacol. 2008 Jun;8(3):275-9. doi: 10.1016/j.coph.2008.02.001. Epub 2008 Mar 14.

Nuclear receptors: doubling up in the lung.

Author information

1
Respiratory Center of Excellence for Drug Discovery, GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK. stuart.n.farrow@gsk.com

Abstract

Inhaled corticosteroids are highly effective in the treatment of asthma and also show efficacy in chronic obstructive pulmonary disease (COPD). Considerable effort continues to be focused on improvement of their pharmacology and pharmacokinetic properties. Corticosteroids act through the glucocorticoid receptor, one of a family of ligand activated transcription factors. These proteins are highly tractable to drug discovery, and are targeted by a number of existing therapeutic agents. The possibility that family members other than the glucocorticoid receptor might have therapeutic benefit in lung disease has received increasing attention. Recent studies using ligands for the vitamin D3 receptor, the peroxisome proliferator-activated receptors, and the liver X receptor have demonstrated significant potential for these novel targets in the treatment of lung disease.

PMID:
18343198
DOI:
10.1016/j.coph.2008.02.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center